[CAS NO. 210110-90-0] Miglustathydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [210110-90-0]

Catalog

HY-17020A

Brand

MCE

CAS

210110-90-0

DESCRIPTION [210110-90-0]

Overview

MDL	-
Molecular Weight	255.74
Molecular Formula	C10H22ClNO4
SMILES	O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O.[H]Cl

For research use only. We do not sell to patients.

2 Publications Citing Use of MCE

Summary

Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease ^[1] ^[2] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05174039	Beyond Batten Disease Foundation\|Theranexus	Batten Disease	February 2, 2022	Phase 1\|Phase 2
NCT00945347	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Cystic Fibrosis	July 2009	Phase 2
NCT00517153	Actelion	Niemann-Pick Type C Disease	January 2002	Phase 2
NCT00742092	Actelion	Cystic Fibrosis	August 2008	Phase 2
NCT04768166	IRCCS Fondazione Stella Maris	Hereditary Spastic Paraparesis	June 15, 2021	Phase 2
NCT03822013	Tehran University of Medical Sciences\|Mashhad University of Medical Sciences\|Kashan University of Medical Sciences	GM2 Gangliosidosis\|Supportive Care	January 14, 2019	Phase 3
NCT02325362	Assistance Publique - Hôpitaux de Paris\|Actelion\|CRCM (Centres de Ressources et de Compétences de la Mucoviscidose)	Cystic Fibrosis	March 17, 2015	Phase 2\|Phase 3
NCT00041535	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Gaucher Disease	July 5, 2002	Phase 2
NCT01760564	National Taiwan University Hospital	Niemann-Pick Disease Type C	January 2008	Phase 3
NCT02030015	University of Minnesota\|Rare Diseases Clinical Research Network\|National Center for Advancing Translational Sciences (NCATS)\|National Institute of Neurological Disorders and Stroke (NINDS)\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|Lysosomal Disease Network	GM1 Gangliosidoses\|GM2 Gangliosidoses\|Tay-Sachs Disease\|Sandhoff Disease	December 22, 2015	Phase 4
NCT02520934	National Taiwan University Hospital\|Actelion	Gaucher Disease	July 2015	Not Applicable
NCT04808505	Amicus Therapeutics	Glycogen Storage Disease Type II Infantile Onset	August 2022	Phase 3
NCT00537602	Actelion	Cystic Fibrosis	November 2007	Phase 2
NCT03910621	Actelion	Niemann-Pick Disease, Type C	April 2, 2020	Phase 4
NCT01451879	University of Florida	Pompe Disease	October 2008
NCT00316498	National Eye Institute (NEI)\|National Institutes of Health Clinical Center (CC)	Niemann Pick Diseases	October 17, 2002	Phase 1
NCT00319046	Actelion	Gaucher Disease Type 1	February 1, 2006	Phase 3
NCT00418847	The Hospital for Sick Children\|Actelion	Gangliosidoses GM2	July 2004	Phase 2
NCT00194649	University of Washington\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Contraception	June 2005	Phase 4
NCT03911505	Amicus Therapeutics	Pompe Disease (Late-onset)	February 13, 2020	Phase 3
NCT00672022	Children´s National Research Institute\|Actelion	GM2 Gangliosidoses\|Tay-Sachs\|Sandhoff Disease	July 2004	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 65 mg/mL ( 254.16 mM ; Need ultrasonic)

H ₂ O : ≥ 34 mg/mL ( 132.95 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9102 mL	19.5511 mL	39.1022 mL
5 mM	0.7820 mL	3.9102 mL	7.8204 mL
10 mM	0.3910 mL	1.9551 mL	3.9102 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (391.02 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3.25 mg/mL (12.71 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 3.25 mg/mL (12.71 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 3.25 mg/mL (12.71 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, hydrochloride (1:1), (2R,3R,4R,5S)-

3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-, hydrochloride, (2R,3R,4R,5S)-

Miglustat hydrochloride